Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin alfa dose-finding induction study in moderately to severely active ulcerative colitis
NL-OMON54105Phase 2Recruiting
- Sponsor
- Amgen
- Start
- May 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efavaleukin alfa in autoimmune colitis (4 arms), sponsored by Amgen. Primary endpoint: Clinical remission at week 12. Started May 2022; status: recruiting.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54105.